Novel synthesis of new triazine sulfonamides with antitumor, anti-microbial and anti-SARS-CoV-2 activities

Mohamed-Ezzat, Reham A.; Elgemeie, Galal H.

doi:10.1186/s13065-024-01164-9

BMC Chemistry

Table 1 Anti-tumor properties of the compounds at a dose of 10 μM using human tumor cell lines

From: Novel synthesis of new triazine sulfonamides with antitumor, anti-microbial and anti-SARS-CoV-2 activities

Panel/Cell line	3a	3b	4a	4b	5a	5b	7b
Leukemia
CCRF-CEM	109.88	100.29	116.66	106.84	96.89	116.52	116.17
HL-60(TB)	112.07	90.58	114.70	114.78	109.12	93.23	78.31
K-562	104.72	91.75	98.62	97.56	92.02	95.72	88.84
MOLT-4	108.90	99.31	98.73	103.63	107.38	99.53	95.99
RPMI-8226	104.02	105.57	100.08	113.68	92.47	99.37	107.97
SR	117.75	98.34	105.41	87.88	90.10	106.56	103.56
Non-small cell lung cancer
A549/ATCC	98.66	98.81	105.02	105.10	105.57	105.50	103.59
EKVX	77.46	80.79	90.29	90.00	80.80	80.41	92.73
HOP-62	85.52	93.97	95.69	98.70	96.56	97.94	102.04
HOP-92	122.02	129.24	89.70	117.23	96.50	91.06	118.08
NCI-H226	93.04	94.32	94.39	98.66	86.85	95.95	96.79
NCI-H23	103.76	94.93	96.92	102.47	92.18	98.55	105.42
NCI-H322M	101.09	98.60	102.91	96.07	99.63	97.47	104.87
NCI-H460	103.67	103.16	103.61	102.31	100.92	100.37	102.22
NCI-H522	98.70	86.83	98.57	93.50	85.01	93.04	94.94
Colon cancer
COLO 205	109.77	117.05	107.26	108.68	104.06	109.34	109.93
HCC-2998	108.67	120.78	110.46	108.19	103.14	110.53	111.51
HCT-116	99.60	100.28	99.11	101.85	98.89	95.84	102.90
HCT-15	96.34	97.17	97.79	99.61	101.80	100.44	98.79
HT29	108.29	116.29	105.23	102.68	104.11	109.46	112.65
KM12	106.63	106.43	109.05	104.54	102.17	101.19	104.16
SW-620	105.70	100.74	101.32	106.70	99.76	98.98	105.00
CNS cancer
SF-268	96.54	98.96	101.29	103.77	95.21	96.49	99.36
SF-295	90.83	86.82	93.19	93.07	86.80	90.82	97.23
SF-539	101.08	92.86	97.24	97.97	89.91	95.16	92.58
SNB-19	98.77	95.13	95.81	95.83	90.09	97.19	95.53
SNB-75	74.76	77.59	77.71	78.73	75.30	77.45	81.18
U251	103.95	99.30	104.64	107.53	97.45	107.68	99.84
Melanoma
LOX IMVI	95.77	94.66	98.93	97.31	89.29	97.71	94.31
MALME-3 M	97.44	84.52	101.06	100.69	93.92	91.01	102.01
M14	102.37	101.94	104.95	98.91	101.13	100.91	99.60
MDA-MB-435	100.60	101.75	98.30	98.72	99.57	100.87	99.48
SK-MEL-2	128.41	102.83	112.24	105.73	116.13	110.65	111.32
SK-MEL-28	99.39	101.04	103.77	101.19	96.01	95.97	97.92
SK-MEL-5	72.98	106.78	92.87	95.62	85.03	95.30	87.34
UACC-257	99.97	103.60	102.15	103.01	111.28	105.19	105.56
UACC-62	103.11	84.71	94.57	94.30	80.87	87.29	94.38
Ovarian cancer
IGROV1	103.94	97.31	110.12	106.47	100.49	89.71	107.05
OVCAR-3	114.38	110.36	106.76	112.06	105.84	106.71	108.62
OVCAR-4	95.65	91.13	86.36	90.71	83.44	85.99	94.63
OVCAR-5	104.49	100.03	103.05	100.77	96.50	91.37	99.69
OVCAR-8	104.22	101.58	104.63	106.02	103.10	101.58	105.11
NCI/ADR-RES	100.60	99.63	103.92	102.27	99.25	101.70	100.28
SK-OV-3	103.08	91.32	107.02	113.01	93.62	98.21	101.24
Renal cancer
786-0	103.15	108.31	110.30	102.34	100.37	101.72	99.30
A498	101.04	110.05	115.02	105.58	103.47	112.37	98.23
ACHN	99.94	98.49	102.14	101.60	91.57	101.12	102.62
CAKI-1	88.61	81.13	92.13	89.24	83.53	86.60	87.08
RXF 393	118.89	105.80	102.59	101.71	90.00	105.38	104.55
SN12C	101.86	96.10	96.05	98.77	85.63	95.34	100.37
TK-10	101.71	134.03	104.72	93.71	107.73	125.56	104.11
UO-31	92.40	81.52	85.43	89.82	81.59	89.98	92.55
Prostate cancer
PC-3	103.05	112.09	106.53	113.83	91.32	107.65	115.88
DU-145	106.44	107.83	109.84	113.40	109.35	105.36	108.61
Breast cancer
MCF7	84.02	87.47	93.45	91.47	90.37	86.42	97.13
MDA-MB-231/ATCC	98.98	90.59	100.13	93.08	88.39	92.68	104.60
HS 578T	99.34	97.30	107.63	113.10	93.30	99.61	111.99
BT-549	104.79	106.72	110.89	109.75	99.59	98.36	105.65
T-47D	94.87	92.07	93.59	98.98	91.58	95.54	99.03

Back to article page

ISSN: 2661-801X

Contact us

Submission enquiries: bmcchemistry@biomedcentral.com
General enquiries: ORSupport@springernature.com